Please login to the form below

Not currently logged in
Email:
Password:

clopidogrel

This page shows the latest clopidogrel news and features for those working in and with pharma, biotech and healthcare.

AZ says Brilinta hits the mark in diabetic heart disease

AZ says Brilinta hits the mark in diabetic heart disease

Last year, the GLOBAL LEADERS study last year also showed that discontinuing aspirin after a month and starting monotherapy with ticagrelor was no better than aspirin plus Brilinta or clopidogrel in

Latest news

  • Another failed trial knocks back AZ's plan to grow Brilinta Another failed trial knocks back AZ's plan to grow Brilinta

    Brilinta (ticagrelor) was unable to show any improvement over an older generic antiplatelet drug - clopidogrel - in the large-scale EUCLID trial, which enrolled almost 14, 000 people with symptomatic PAD. ... Billed as the largest cardiovascular outcomes

  • AZ's Brilinta disappoints in stroke trial AZ's Brilinta disappoints in stroke trial

    superiority to Sanofi's Plavix (clopidogrel), a former blockbuster now subject to generic competition.

  • FDA approval keeps AZ on track with ambitious Brilinta plans FDA approval keeps AZ on track with ambitious Brilinta plans

    Brilinta was previously approved as 90mg tablet given twice-daily after being shown to be superior to clopidogrel in the PLATO trial, and the new indication gives a green light to ... However, it has been suggested the PEGASUS data could also lead to

  • FDA gives the nod to TMC's antiplatelet drug FDA gives the nod to TMC's antiplatelet drug

    into a market formerly dominated by Sanofi's Plavix (clopidogrel) which lost patent protection in 2012. ... The overall occurrence of serious bleeding was low but more common with Kengreal than with clopidogrel, with one in every 170 Kengreal-treated

  • Heart drug sales continue downward spiral Heart drug sales continue downward spiral

    Sanofi has a number of CV medicines including Aprovel (irbesartan), Lovenox (enoxaparin) and the co-marketed Plavix (clopidogrel), which collectively made the firm 4.2bn euro ($4.7bn) last year, helping

More from news
Approximately 1 fully matching, plus 76 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily aspirin and/or clopidogrel to reduce thrombotic cardiovascular events.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics